auto_awesome_motion View all 3 versions
organization

NICE

National Institute for Health and Care Excellence
Country: United Kingdom
17 Projects, page 1 of 4
  • Open Access mandate for Publications and Research data
    Funder: EC Project Code: 821513
    Overall Budget: 2,353,120 EURFunder Contribution: 1,199,120 EUR
    Partners: NICE, TAKEDA, PARKINSON'S UK, TPIZ, AE, Janssen (Belgium), Roche (Switzerland), Eli Lilly and Company Limited, SARD, SYNAPSE RESEARCH MANAGEMENT PARTNERS SL

    The main aim of NEURONET is to set up an efficient platform to boost synergy and collaboration across the IMI projects of the Neurodegenerative Disorders (ND) portfolio, assisting in identifying gaps, multiplying its impact, enhancing its visibility and facilitating dovetailing with related initiatives in Europe and worldwide. This will be achieved through the following specific objectives: 1) creation of an overall platform for efficient collaboration, communication and operational synergies among present and future IMI ND projects; 2) designing systems to map and analyse information regarding actions, initiatives and partnerships, assessing impact of the individual projects, remaining gaps and global value of the programme for stakeholders; 3) supporting the management of the programme (timelines, dependencies, synergies and key results across projects); 4) proactively detecting needs, opportunities and transferable best practices of projects and to connect them; 5) providing support to the projects by organising tools, services, expert advice and guidelines/recommendations on common issues; 6) promoting enhancement and coordination of communication across the IMI neurodegeneration projects, increasing programme visibility, outreaching to key stakeholders and establishing relationships with initiatives in the field; and 7) preparing and securing the long-term sustainability of NEURONET itself. Achievement of these objectives will necessarily rely on buy-in from existing and future projects in the IMI ND portfolio, and effective connections with other programmes and initiatives in Europe and beyond, including stakeholder representation. For this, the Consortium has been constituted by very active partners in a variety of IMI ND projects and related initiatives with specialists in areas like complex/project management, data sharing & re-use, drug development, patient engagement, communication, sustainability and regulatory/HTA interactions.

  • Open Access mandate for Publications
    Funder: EC Project Code: 602270
    Partners: LELAN LTD, NCSCT COMMUNITY INTEREST COMPANY, Brunel University London, NHS COMMISSIONING BOARD, SYREON, ENSP, Helmholtz Zentrum München, NICE, UM, AGENCIJA ZA KVALITETU I AKREDITACIJU U ZDRAVSTVU I SOCIJALNOJ SKRBI...
  • Open Access mandate for Publications
    Funder: EC Project Code: 258583
    Partners: THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN, University Medical Center Freiburg, AMC, NOKC, IR-HSCSP, University of Dundee, KUSTANNUS OY DUODECIM, NICE, AREAS-CCI, WHO...
  • Open Access mandate for Publications
    Funder: EC Project Code: 305983
    Partners: AHTAPOL, EASP, ISTITUTO SUPERIORE DI SANITA, UCLM, LSHTM, LSE, TUB, UPEC, NICE, EBC...
  • Open Access mandate for Publications and Research data
    Funder: EC Project Code: 825162
    Overall Budget: 9,640,780 EURFunder Contribution: 9,640,780 EUR
    Partners: University of York, Utrecht University, Medical University of Sofia, SYREON, UB, UPM, NICE, EORTC, Zorginstituut Nederland, University of Oulu...

    HTx will create a framework for next generation Health Technology Assessment (HTA) that supports patient-centred, societally oriented, and real-time decision-making for integrated healthcare throughout Europe. HTx will focus on therapeutic areas with high unmet need for which HTA information has to be provided on complex and personalised combinations of health technologies. Based on a select number of relevant case studies, HTx will enhance methods for integrating evidence from RCTs and real-world data (RWD). HTx will also augment statistical and econometric methods for generating robust estimates of effectiveness and cost-effectiveness in order to support relevant HTA decision-making for these complex and personalised combinations of health technologies. HTx will also contribute to improving methods to support personalised treatment advice fitted for sharing with patients and their physicians. This includes the development of statistical and econometric approaches and artificial intelligence/machine learning methods for forecasting treatment effects in specific groups of patients. Simultaneously, in close collaboration with the European Network for HTA (EUnetHTA), HTx will improve synergies between regulatory agencies, HTA bodies and clinical guideline developers. This will include the translation of HTx methods into already existing European guidelines, most prominently those developed by EUnetHTA. HTx will also support initial efforts to discuss reimbursement and funding models that facilitate controlled access to and the pricing of these complex health technologies. Finally, we will evaluate the transferability of HTx results into all EU Member Countries especially in Central and Eastern European (CEE) Countries and promote the dissemination of HTx results to the different European stakeholders with a special focus on the patient community.